Hepatitis%20b News

News

Switch from TDF to TAF does not affect viral suppression in chronic HBV

Roshini Claire Anthony, 20200910200001

In virologically suppressed patients with chronic hepatitis B virus (HBV) infection, switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) did not affect their rates of viral suppression, according to the final 96-week analysis of a phase III study.

Trivalent hep B vaccine yields robust immune response

Pearl Toh, 20200907150010

A trivalent vaccine against hepatitis (hep B) is safe and effectively elicits robust immune response compared with a monovalent Hep B vaccine, according to the PROTECT and CONSTANT studies presented during the 2020 digital ILC.

Hepatitis B cure: Several investigational drugs shoot at victory

Jairia Dela Cruz, 20200903140000

Hope for a hepatitis B virus cure becomes manifest as multiple drugs from recent clinical trials show potential in transforming the battle against the disease.

Tenofovir delivers better protection against HCC than entecavir in HBV patients

Jairia Dela Cruz, 20200528080000

Persistent hepatitis B virus (HBV) replication contributes to an increased risk of hepatocellular carcinoma (HCC), and suppressing this replication with tenofovir disoproxil fumarate yields greater HCC risk reduction than with entecavir, according to the results of a meta-analysis.

Infection prevalence increased before cancer diagnosis

Roshini Claire Anthony, 20200515140001

Individuals who develop cancer may have an elevated risk of certain infections in the years leading up to their diagnosis, a retrospective case-control study from Japan showed.

TAF an alternative to TDF as maintenance for chronic HBV

Roshini Claire Anthony, 20200413140003

Patients with chronic hepatitis B virus (HBV) infection who are virologically suppressed after treatment with tenofovir disoproxil fumarate (TDF) could potentially switch to tenofovir alafenamide (TAF), according to a recent phase III study.

HBeAg status implicated in liver pathology in chronic hepatitis B

20200120060000

Patients with chronic hepatitis B (CHB) virus infection who are HBeAg-negative are more likely to have advanced liver fibrosis than those with a positive HBeAg status, a study has found.

Besifovir safe, effective for treating chronic hepatitis B virus infection in Asians

Jairia Dela Cruz, 20190820130000

Besifovir dipivoxil maleate has antiviral efficacy against chronic hepatitis B that is similar to that of tenofovir disoproxil fumarate but with a lower impact on bone and renal safety, as shown in the results of a phase III trial involving Asian patients.

Is stopping long-term nucleotide analogue treatment beneficial in chronic HBV?

Roshini Claire Anthony, 20190322140202

A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.

Besifovir on par with tenofovir for hepatitis B virus, but safer

20181210060000

Besifovir dipivoxil maleate (BSV) for hepatitis B virus infection produces lasting effects and is as good as tenofovir disoproxil fumarate, according to the results of a phase III trial. However, BSV has a better safety profile with respect to bone and renal outcomes.

Product Highlight - Salofalk

12 Mar 2021

SALOFALK – Mesalazine 1.5 g PR granules

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.

Product Highlight - Ravida

13 Sep 2022

Ravidasvir 200 mg tab